Protalix Biotherapeutics Inc Stock TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 187M 0 163M 150M 140M 265M 17.8B 270M 1.81B 700M 8.73B 702M 687M 30.08B | P/E 2026 * |
11.9x | P/E 2027 * | 46.4x |
|---|---|---|---|---|---|
| Enterprise Value | 187M 0 163M 150M 140M 265M 17.8B 270M 1.81B 700M 8.73B 702M 687M 30.08B | EV / Sales 2026 * |
2.39x | EV / Sales 2027 * | 2.77x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 58 | 2019-06-29 |
Gilad Mamlok
DFI | Director of Finance/CFO | 58 | 2025-08-23 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 2024-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 2008-06-30 |
Aharon Schwartz
BRD | Director/Board Member | 82 | 2014-10-31 |
Dror Bashan
BRD | Director/Board Member | 58 | 2019-06-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 187M | |
| +3.45% | +7.65% | +55.77% | +158.84% | 1,082B | |
| -1.16% | +7.42% | +69.09% | +58.92% | 633B | |
| -0.77% | +7.37% | +36.87% | +93.77% | 461B | |
| +3.15% | -1.94% | +26.41% | +20.22% | 339B | |
| -0.48% | +0.77% | +41.40% | +39.08% | 301B | |
| -0.11% | +1.01% | +31.78% | +44.07% | 292B | |
| -1.78% | +2.52% | -25.57% | -39.78% | 225B | |
| +3.55% | +6.05% | +26.04% | +68.52% | 202B | |
| +0.40% | +6.00% | +17.72% | +70.33% | 163B | |
| Average | +1.20% | +4.52% | +31.06% | +57.11% | 411.08B | |
| Weighted average by Cap. | +1.35% | +5.21% | +41.69% | +81.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 78.3M 0 68.42M 62.83M 58.59M 111M 7.45B 113M 756M 293M 3.66B 294M 288M 12.6B | 67.56M 0 59.04M 54.21M 50.56M 95.84M 6.43B 97.46M 653M 253M 3.15B 254M 248M 10.87B |
| Net income | 15.72M 0 13.74M 12.62M 11.76M 22.3M 1.5B 22.68M 152M 58.87M 734M 59.03M 57.75M 2.53B | 4.07M 0 3.56M 3.27M 3.05M 5.78M 388M 5.88M 39.35M 15.25M 190M 15.3M 14.96M 655M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
